tbuckley/cabot-search huggingface dataset:
Association of Demographic and Socioeconomic Characteristics With Differences in Use of Outpatient Dermatology Services in the United States
Authors: Raghav Tripathi, Konrad D. Knusel, Harib H. Ezaldein, Jeffrey F. Scott, Jeremy S. Bordeaux
Journal: JAMA Dermatology (2018)

Knowledge regarding differences in dermatologic care for patients with a broad range of dermatologic conditions is limited.To elucidate nationwide differences in use of outpatient dermatologic care.Retrospective analysis of nationally representative data from the 2007 to 2015 Medical Expenditure Panel Survey (MEPS) provided by the Agency for Healthcare Research and Quality. Health care use outcomes for dermatologic conditions (skin cancers, infections, dermatologic inflammatory conditions/ulcers, and other skin disorders) were examined via multivariable logistic regression analyses of outpatient and office-based dermatologist visit rates accounting for sex, age, race/ethnicity, educational level, income, insurance status, region, self-reported condition, and self-reported health status. Participants were 183 054 MEPS respondents who visited a dermatologist from 2007 to 2015.The primary outcome measure was whether the patient received outpatient care for any dermatologic condition (by payment). The secondary outcomes were annual health care use by individuals with dermatologic conditions (including per capita expenditure for the visit).Of 183 054 MEPS respondents (mean [SD] age, 34 [23] years; 52.1% female), 19 561 (10.7%) self-reported a dermatologic condition; 9645 patients had a total of 11 761 outpatient visits to dermatologists. Hispanic (adjusted odds ratio [aOR], 0.55; 95% CI, 0.49-0.61) and black (aOR, 0.42; 95% CI, 0.38-0.46) patients were both less likely to receive outpatient care for their dermatologic condition relative to non-Hispanic white patients. Male patients were less likely to receive outpatient dermatologic care than female patients (aOR, 0.66; 95% CI, 0.62-0.70), and Midwestern patients were less likely to receive outpatient dermatologic care than Northeastern patients (aOR, 0.80; 95% CI, 0.70-0.91). Patients with Medicaid or Medicare coverage (aOR, 0.75; 95% CI, 0.68-0.83) and uninsured patients (aOR, 0.39; 95% CI, 0.33-0.47) were both less likely to receive outpatient dermatologic care than privately insured patients. Increasing educational level and income were associated with increased odds of receiving outpatient care for the dermatologic condition.These findings highlight wide-ranging differences in use of dermatologic care in the United States across various demographic and socioeconomic lines. Results of this study suggest an urgent need to further characterize potential dermatologic health care differences and improve use of outpatient dermatologic care among disadvantaged populations.
Abstract 17211: Left Atrial Strain Adds Prognostic Value to Left Ventricular Global Longitudinal Strain in Heart Failure Patients Treated by Cardiac Resynchronization Therapy With Intermediate Electrocardiographic Criteria
Authors: Masataka Sugahara, Nobuyuki Kagiyama, Nina E Hasselberg, Evan Adelstein, John Gorcsan
Journal: Circulation (2017)

Introduction: Response to cardiac resynchronization therapy (CRT) has been difficult to predict in heart failure (HF) patients with QRS width 120-149ms or non-left ventricular brunch block (LBBB), ...
How to: EUCAST recommendations on the screening procedure E.Def 10.1 for the detection of azole resistance in Aspergillus fumigatus isolates using four-well azole-containing agar plates
Authors: J. Guinea, P.E. Verweij, J. Meletiadis, J.W. Mouton, F. Barchiesi, M.C. Arendrup, M.C. Arendrup, S. Arikan-Akdagli, F. Barchiesi, M. Castanheira, E. Chryssanthou, N. Friberg, J. Guinea, H. Järv, N. Klimko, O. Kurzai, K. Lagrou, C. Lass-Flörl, M. Mares, T. Matos, J. Meletiadis, C.B. Moore, J.W. Mouton, K. Muehlethaler, T.R. Rogers, C.T. Andersen, A. Velegraki
Journal: Clinical Microbiology and Infection (2018)
Abstract 15604: Triglyceride-rich Lipoproteins Linked to Migraine in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil)
Authors: Alessandra C Goulart, Paulo A Lotufo, Itamar S Santos, Márcio S Bittencourt, Raul D Santos, Michael J Blaha, Steven Jones, Peter P Toth, Isabela M Benseñor
Journal: Circulation (2016)

Background and Purpose: Migraine headache has previously been associated with dyslipidemia. However, no epidemiological study has investigated the association of migraine with an advanced blood lip...
Abstract 20070: Hypoxic Reprogramming of Exosomal miRNAs by Ets Transcription Factors in Human CD34+ Stem Cells Promotes Ischemic Tissue Repair
Authors: David Kim, Douglas E Vaughan, Susan E Quaggin, Douglas W Losordo, Susmita Sahoo
Journal: Circulation (2014)

Introduction: In a first study of its kind, we have demonstrated a novel mechanism that therapeutic human CD34+ stem cells secrete membrane bound nano-sized vesicles called exosomes (Exo) into their paracrine secretion. Our preliminary data suggests that cell-free Exo mimic the angiogenic and therapeutic activity of CD34+ cells and carry several proangiogenic miRNAs, such as miR-126 that affects their function. Hypothesis: We hypothesized that the regenerative efficacy of the cell-free CD34Exo can be improved by hypoxic pre-conditioning, modulating its pro-angiogenic miRNA content. Methods and Results: Exosomes from human peripheral blood-derived CD34+ cells cultured under hypoxia (H-Exo) were significantly more proliferative, anti-apoptotic and angiogenic in vitro, as compared to exosomes from cells under normoxia (N-Exo). Treatment with H-Exo significantly improved perfusion (ratio: 0.93±0.05 v 0.77±0.02), increased capillary density (1.6±0.2 v 1.1±0.1/HPF) and prevented ischemic limb amputation (0% v 3...
(Mid)West Side Story: Acute Hepatitis C Virus Infection and the Opioid Epidemic in the United States
Authors: Christoph Boesecke, Jürgen K. Rockstroh
Journal: Hepatology (2018)

Boesecke, Christoph M.D.; Rockstroh, Jürgen K. M.D.Editor(s): Corey, Kathleen E.2; Malhi, Harmeet3 Author Information
The impact of routine ESAS use on receiving palliative care services: Results of a population-based retrospective matched cohort analysis.
Authors: Lisa Catherine Barbera, Rinku Sutradhar, Craig Earle, Nicole Mittmann, Hsien Seow, Doris Howell, Qing Li, Thiruchelvam Deva
Journal: Journal of Clinical Oncology (2018)

191 Background: In 2007 Cancer Care Ontario began standardized symptom assessment as part of routine clinical care using the Edmonton Symptom Assessment System (ESAS). The purpose of this project was to evaluate the impact of this program on referrals to palliative care. We hypothesized that patients exposed to ESAS would be more likely to be referred. Methods: A retrospective matched cohort study was conducted to examine the impact of ESAS screening on the initiation of palliative care services provided by physician or homecare nurse among newly diagnosed cancer patients in Ontario, Canada. The study included all adult patients who were diagnosed with cancer between 2007 and 2015. Exposure was defined as completing ≥1 ESAS during the study period. Using four hard matched variables and propensity-score matching with 14 variables, cancer patients exposed to ESAS were matched 1:1 to those who were not. Matched patients were followed from first ESAS until initiation of palliative care, death or the end of study at Mar 31, 2017. Results: The final cohort consisted of 204,688 matched patients with no prior palliative care consult. The pairs were well matched. The probability of receiving palliative care within the first 5 years was higher among those exposed to ESAS compared to those who were not (20.6% vs. 15.2%, p &lt; .0001). The risk of death without receipt of palliative care within the same period was low in both groups. In the adjusted cause-specific Cox proportional hazards model, ESAS assessment was associated with a 6% increase in palliative care services (HR: 1.06, 95% CI: 1.04-1.08). Conclusions: Cancer patients who completed ESAS were more likely to initiate palliative care services than those who didn’t. ESAS screening may help identify patients who would benefit from a palliative approach to care earlier in their clinical course.
Abstract 14484: Improving Dietary Habits in High Risk Employees of a Large Health Care Organization
Authors: Sankalp Das, Maribeth Rouseff, Henry E Guzman, Natalie D Castro, Teresa C Ochoa, Joseph Mora, Cynthia Gilliam, Doris Brown, Virginia Lehn, Shoshana B Sherriff, Ehimen C Aneni, Emir Veledar, Theodore Feldman, Chukwuemeka U Osondu, Joann Santiago-Charles, Thinh H Tran, Oluseye Ogunmoroti, Alena C Costume, Amett Pino, April Weatherly, Brian Betancourt, Erin Leigh, Francisco Jou, Georgelena Saborio, Ivan Saavedra, Jim Cleary, Lynn McCauley, Mary Desimone, Matthew Romney, Khurram Nasir
Journal: Circulation (2016)

Introduction: There is a lack of information on whether employee wellness programs can succeed in improving longer-term dietary patterns in high risk employees. In the current study, we present die...
Angiopoietin‐2 Promotes Pathological Angiogenesis and Is a Therapeutic Target in Murine Nonalcoholic Fatty Liver Disease
Authors: Sander Lefere, Frederique Van de Velde, Anne Hoorens, Sarah Raevens, Sanne Van Campenhout, Astrid Vandierendonck, Sara Neyt, Bert Vandeghinste, Christian Vanhove, Charlotte Debbaut, Xavier Verhelst, Jo Van Dorpe, Christophe Van Steenkiste, Christophe Casteleyn, Bruno Lapauw, Hans Van Vlierberghe, Anja Geerts, Lindsey Devisscher
Journal: Hepatology (2018)

Angiogenesis contributes to the development of nonalcoholic steatohepatitis (NASH) and promotes inflammation, fibrosis, and progression to hepatocellular carcinoma (HCC). Angiopoietin‐2 (Ang‐2) is a key regulator of angiogenesis. We aimed to investigate the role of Ang‐2 and its potential as a therapeutic target in NASH using human samples, in vivo mouse models, and in vitro assays. Serum Ang‐2 levels were determined in 104 obese patients undergoing bariatric surgery and concomitant liver biopsy. The effect of the Ang‐2/Tie2 receptor inhibiting peptibody L1‐10 was evaluated in the methionine‐choline deficient (MCD) and streptozotocin‐western diet nonalcoholic fatty liver disease mouse models, and in vitro on endothelial cells and bone marrow–derived macrophages. The hepatic vasculature was visualized with µCT scans and scanning electron microscopy of vascular casts. Serum Ang‐2 levels were increased in patients with histological NASH compared with patients with simple steatosis and correlated with hepatic CD34 immunoreactivity as a marker of hepatic angiogenesis. Serum and hepatic Ang‐2 levels were similarly increased in mice with steatohepatitis. Both preventive and therapeutic L1‐10 treatment reduced hepatocyte ballooning and fibrosis in MCD diet‐fed mice and was associated with reduced hepatic angiogenesis and normalization of the vascular micro‐architecture. Liver‐isolated endothelial cells and monocytes from MCD‐fed L1‐10–treated mice showed reduced expression of leukocyte adhesion and inflammatory markers, respectively, compared with cells from untreated MCD diet‐fed mice. In the streptozotocin‐western diet model, therapeutic Ang‐2 inhibition was able to reverse NASH and attenuate HCC progression. In vitro , L1‐10 treatment mitigated increased cytokine production in lipopolysaccharide‐stimulated endothelial cells but not in macrophages. Conclusion: Our findings provide evidence for Ang‐2 inhibition as a therapeutic strategy to target pathological angiogenesis in NASH.
Want to improve return to sport outcomes following injury? Empower, engage, provide feedback and be transparent: 4 habits!
Authors: Jonny King, Craig Roberts, Steve Hard, Clare L Ardern
Journal: British Journal of Sports Medicine (2018)

A major limitation of the traditional return to sport (RTS) decision has been the exclusion of the athlete in question.1 Recently, two frameworks have underscored the importance of involving the athlete in a multidisciplinary team (MDT) and putting them at the centre of a shared decision-making process that collectively decides RTS protocol.2 3 RTS should also be considered as a continuum that begins at the onset of injury, rather than an isolated step occurring at the end of rehabilitation.3 It should be a process that fosters athlete autonomy; this has been shown to promote personal development, improve motivation and task performance, and subsequently improve rehabilitation outcomes.4 

To date, little has been published on the practicality of integrating these principles into a rehabilitation programme within a high-performance environment. The purpose of this editorial is to outline four key habits that clinicians and practitioners can focus on to improve RTS outcomes and maximise rehabilitation outputs : empowerment, engagement, feedback and being transparent. We refer to this as the ‘athlete-centred return to sport approach’ (figure 1).



Figure 1 
The process framing our athlete-centred return to sport approach.



### Empower the athlete

Educate the athlete early about their injury. Take the time to describe potentially injured structures and explain the basic stages of tissue healing. Having this conversation within the first days of injury is an opportunity to empower the athlete early in taking ownership of their rehabilitation. An example of this would be educating the athlete how they can modify their nutrition to optimise recovery during the acute phase of injury. We have found that these early discussions can help establish a strong collaborative working relationships between the athlete and clinician for the journey from injury through to RTS and performance. It also reminds the athlete that RTS starts from the very moment of …
Abstract 13464: Pentraxin 3 is Uninfluenced by High Doses of Concentrated Omega-3 Fatty Acids Administered for 12 Months Following an Acute Myocardial Infarction
Authors: Volker Poenitz, Heidi Grundt, Barbara Bottazzi, Ivan Cuccovillo, Alberto Mantovani, Dennis W Nilsen
Journal: Circulation (2012)

Background: Treatment with n-3 fatty acids has shown to improve outcome in patients with myocardial infarction (MI). However, the pathophysiological mechanisms of their beneficial effect are still being debated. Although anti-inflammatory mechanisms have been postulated, their influence on high sensitivity C-reactive protein (hs-CRP) is controversial. Hs-CRP belongs to the pentraxin family, so also does the recently identified long pentraxin 3 (PTX3) which has been found to reflect the inflammatory state of the vasculature and has been shown to predict outcome in MI patients. The aim of the present analysis was to assess the effect of long-term treatment with high doses of omega-3 fatty acids on circulating plasma levels of PTX3. Methods: In the OFAMI study (ClinicalTrials.gov; NCT01422317), 300 MI patients were randomised to blindly receive 4 gelatine capsules of omega-3 in a concentrated ethylester form, each capsule containing 850-882 mg eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (Omaco...
Abstract 13757: A Nationwide Trial of Screening for Undiagnosed Atrial Fibrillation in an At-Risk Population Using a Self-Applied ECG Recording Patch Sensor: Results of the Randomized Component of the mHealth Screening to Prevent Strokes (mSToPS) Trial
Authors: Steven R Steinhubl, Jill Waalen, Alison M Edwards, Rajesh R Mehta, Lauren Ariniello, Gail Ebner, Katie Baca-Motes, Chureen Carter, Elise Felicione, Troy Sarich, Eric J Topol
Journal: Circulation (2017)

Introduction: Undiagnosed atrial fibrillation (AF) can lead to strokes, the majority of which could be prevented through use of oral anticoagulants. Therefore, guidelines recommend opportunistic sc...
Antiphospholipid Syndrome Following Pembrolizumab Treatment of Stage IIIB Unresectable Melanoma
Authors: Adrien Sanchez, Henri Montaudie, Pierre Bory, Xavier Belgodere, Thierry Passeron, Jean Philippe Lacour, Alexandra Picard
Journal: JAMA Dermatology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer’s disease
Authors: Hua Zhang, Kok Pin Ng, Joseph Therriault, Min Su Kang, Tharick A. Pascoal, Pedro Rosa-Neto, Serge Gauthier
Journal: Translational Neurodegeneration (2018)

Visinin-like protein-1 (VILIP-1) and chitinase-3-like protein 1 (CHI3L1 or YKL-40) in cerebrospinal fluid (CSF) are newly discovered markers indicating neuronal damage and microglial activation, respectively. Phosphorylated tau (p-tau) reflects the neuropathology of Alzheimer's disease (AD) and is useful as diagnostic markers for AD. However, it is unknown whether these biomarkers have similar or complementary information in AD.We stratified 121 participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database into cognitively normal (CN), stable mild cognitive impairment (sMCI), progressive MCI (pMCI), and dementia due to AD. Analysis of covariance (ANOVA) and chi-square analyses, Spearman correlation, and logistic regression models were performed to test the demographic, associations between biomarkers, and diagnostic accuracies, respectively. Linear mixed-effects models were used to evaluate the effects of CSF amyloid-β (Aβ) on above biomarkers within diagnostic groups, the combination of diagnostic group and Aβ status as predictor, and CSF biomarkers as predictors of AD features, including cognition measured by Mini-Mental State Examination (MMSE) and brain structure and white matter hyperintensity (WMH) measured by magnetic resonance imaging (MRI).P-tau, VILIP-1, and YKL-40 were all predictors of AD diagnosis, but combinations of biomarkers did not improve the diagnostic accuracy (AUC 0.924 for p-tau, VILIP-1, and YKL-40) compared to p-tau (AUC 0.922). P-tau and VILIP-1 were highly correlated (r = 0.639, p < 0.001) and strongly associated with Aβ pathology across clinical stages of AD, while YKL-40 was correlated with Aβ pathology in CN and AD groups. VILIP-1 was associated with acceleration of cognitive decline, hippocampal atrophy, and expansion of ventricles in longitudinal analyses. YKL-40 was associated with hippocampal atrophy at baseline and follow-up, while p-tau was only associated with worsening WMH at baseline.CSF levels of p-tau, VILIP-1, and YKL-40 may have utility for discriminating between cognitively normal subjects and patients with AD. Increased levels of both VILIP-1 and YKL-40 may be associated with disease degeneration. These CSF biomarkers should be considered for future assessment in the characterization of the natural history of AD.
Pathology quality improvement in British Columbia using performance measurement and knowledge mobilization.
Authors: Nick van der Westhuizen, Cheng-Han Lee, Brigette Rabel, Katherine Young, Shaheena Mukhi
Journal: Journal of Clinical Oncology (2018)

54 Background: Pathology reporting content and formatting varies considerably in British Columbia (BC). The impact of this variability on the quality of care is unknown but it hinders effective data collection and measurement to guide quality improvement. A knowledge mobilization project that digitalized standardized reporting would ensure report completeness and generation of comparative performance data could be used within communities of practice to facilitate peer-to-peer conversations and create action plans to improve patient care. Methods: In 2014 BC adopted the College of American Pathologists cancer checklists as the standard for synoptic reporting using a single standalone electronic synoptic reporting program which interfaced with all five provincial laboratory information systems. Using the tool ensures all mandatory clinical prognostic indicators are reported. Discrete data elements were transmitted to a central data repository (CDR) which was mined to compile key performance indices reports for individual pathologists and generate comparative data reports at the institutional, regional and provincial level. Results: In the first six months of its implementation there was variation from 11-94% across different laboratories in their adoption of the reporting tool. The goal is to increase the average adoption rate from 76% to 90%. Analysis of data showed a highly comparable pattern of pathology practice across the major cancer sites/types and comparable to other Canadian provinces and the literature. Advisory committee reviews with interdisciplinary discussion of comparative data reports revealed potential areas for clinical improvement. For example, significant variation in the number of lymph nodes in colorectal resections was identified with some sites falling short of published recommendations. Conclusions: Population-based standardized digitalized pathology data reporting with centralized data collection can be achieved. Analysis of this data enables monitoring of performance metrics and meaningful discussions via communities of practice identify areas for quality improvement and create action plans.
The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity
Authors: Jan P. Böttcher, Caetano Reis e Sousa
Journal: Trends in cancer (2018)

Dendritic cells (DCs) are key orchestrators of immune responses. A specific DC subset, conventional type 1 DCs (cDC1s), has been recently associated with human cancer patient survival and, in preclinical models, is critical for the spontaneous rejection of immunogenic cancers and for the success of T cell-based immunotherapies. The unique role of cDC1 reflects the ability to initiate de novo T cell responses after migrating to tumor-draining lymph nodes, as well as to attract T cells, secrete cytokines, and present tumor antigens within the tumor microenvironment, enhancing local cytotoxic T cell function. Strategies aimed at increasing cDC1 abundance in tumors and enhancing their functionality provide attractive new avenues to boost anti-tumor immunity and overcome resistance to cancer immunotherapies.